Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Balaji Prasad. I'm the Senior Analyst for the Specialty Pharmaceuticals sector for Barclays. It is my privilege to kick off our SpecPharma track with Teva Pharmaceuticals.
And I had the privilege of hosting Richard here on stage with me, CEO of Teva. I also do want to call out Eli Kalif, CFO of Tewa, not on the stage but on the front row, and Chris and Dave and Sanjeev from the Teva team.
Thank you all for joining us and to all our investors, thank you for joining us here in Miami. So starting with, it's been a great call for us over the last couple of years. The turnaround has been exceptional and recently the company also reported its Q4 and gave over its 2025 outlook. We saw a bit of sell off posters, but in terms of the pipeline progress in terms of the execution and true stabilisation of the business, it has been a phenomenally impressive one. So I hand it over to Richard to start with some opening remarks with your recent earnings and your '25 outlook and then take some questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
